Qlaris Bio, Inc.
9
2
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Role: lead
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Role: lead
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
Role: lead
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Role: lead
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Role: lead
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
Role: lead
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
Role: lead
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
Role: lead
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Role: lead
All 9 trials loaded